Endocrine Foundations of PCOS

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects up to 10 % of women of reproductive age. Understanding the terminology that underpins the endocrine foundations of PCOS is essential for clinicians, researchers, and allied health professionals who manage this condition at a postgraduate level. The following comprehensive glossary presents the most frequently encountered terms, their physiological relevance, clinical implications, and common challenges in interpretation. Each entry is designed to be learner‑friendly, with practical examples and notes on how the concept integrates into patient care.

Hyperandrogenism refers to the excessive production of androgens by the ovaries, adrenal glands, or peripheral conversion of precursors. In PCOS, hyperandrogenism manifests clinically as hirsutism, acne, and androgenic alopecia. Biochemically, total and free testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEA‑S) are measured. A common challenge is the variability of assay methods; immunoassays may overestimate low levels, whereas liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) provides greater specificity. For instance, a woman presenting with moderate hirsutism may have a total testosterone of 55 ng/dL measured by LC‑MS/MS, which exceeds the laboratory‑specific upper limit of 46 ng/dL, confirming biochemical hyperandrogenism.

Insulin resistance (IR) is a reduced cellular response to insulin, leading to compensatory hyperinsulinaemia. IR is present in approximately 50‑70 % of women with PCOS, irrespective of body mass index (BMI). The pathophysiological link between IR and ovarian androgen excess is mediated by insulin’s synergistic effect on theca‑cell steroidogenesis, amplifying LH‑stimulated androstenedione production. Clinically, IR may be identified using the fasting insulin‑glucose ratio, the homeostatic model assessment of insulin resistance (HOMA‑IR), or dynamic tests such as the oral glucose tolerance test (OGTT). A practical example: A patient with a fasting glucose of 92 mg/dL and fasting insulin of 18 µU/mL yields a HOMA‑IR of 4.1, Indicating significant insulin resistance that may warrant metformin therapy.

Luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) are gonadotropins secreted by the anterior pituitary under the control of gonadotropin‑releasing hormone (GnRH) pulsatility. In PCOS, an increased frequency of GnRH pulses preferentially stimulates LH synthesis, resulting in an elevated LH/FSH ratio, commonly quoted as >2.5. The heightened LH surge drives theca‑cell androgen synthesis, while relatively low FSH limits follicular maturation, contributing to anovulation. An example of interpretation: A woman with a serum LH of 12 IU/L and FSH of 4 IU/L has an LH/FSH ratio of 3.0, Supporting the diagnosis of PCOS when combined with other criteria.

Anti‑Müllerian hormone (AMH) is produced by granulosa cells of pre‑antral and small antral follicles. AMH levels are typically elevated in PCOS, reflecting the increased follicle count. AMH serves as a surrogate marker for ovarian reserve and can aid in diagnosing PCOS, especially in adolescents where menstrual patterns are still stabilising. However, assay heterogeneity and lack of universally accepted cut‑offs pose challenges. For example, an AMH of 7.5 Ng/mL measured by a second‑generation ELISA may be considered above the 95th percentile for women aged 20‑30, reinforcing the presence of polycystic ovarian morphology.

Ovulatory dysfunction encompasses a spectrum from oligo‑ovulation (infrequent ovulation) to anovulation (absence of ovulation). Clinically, this manifests as irregular menstrual cycles, amenorrhoea, or oligomenorrhoea. The underlying endocrine disturbances include disrupted LH/FSH dynamics, hyperandrogenism, and insulin resistance. In practice, ovulatory status is often assessed by mid‑cycle serum progesterone; a level <3 ng/mL in the luteal phase suggests anovulation. A case scenario: A patient with a 45‑day cycle reports a luteal progesterone of 1.2 Ng/mL, confirming ovulatory dysfunction that may be addressed with ovulation induction agents.

Androgen excess phenotype is one of the three phenotypic classifications derived from the Rotterdam criteria: (1) Hyperandrogenism plus ovulatory dysfunction, (2) hyperandrogenism plus polycystic ovarian morphology (PCOM), and (3) hyperandrogenism alone. Women with the androgen excess phenotype often experience more severe metabolic disturbances, including higher rates of dyslipidaemia and glucose intolerance. Recognising this phenotype guides targeted therapeutic strategies, such as early introduction of insulin‑sensitising agents.

Polycystic ovarian morphology (PCOM) is defined on trans‑vaginal ultrasound as the presence of ≥20 follicles measuring 2‑9 mm in each ovary, or an ovarian volume >10 cm³. The diagnostic threshold varies with the ultrasound equipment’s resolution; high‑frequency probes may detect smaller follicles, potentially inflating PCOM prevalence. A practical tip: When using a 8‑MHz probe, the follicle count cutoff may be reduced to ≥12 to maintain specificity. Radiologists should document both the follicle count and ovarian volume to support the diagnosis.

Rotterdam criteria constitute the most widely adopted diagnostic framework for PCOS. They require the presence of any two of the following three features: (I) oligo‑ or anovulation, (ii) clinical or biochemical hyperandrogenism, and (iii) PCOM on ultrasound, after exclusion of other androgen‑excess disorders. While the Rotterdam criteria increase diagnostic sensitivity, they also broaden the phenotypic spectrum, leading to debates about over‑diagnosis. Clinicians must balance inclusivity with the risk of labeling women who may have milder metabolic derangements.

NIH criteria are more stringent, requiring both hyperandrogenism and oligo‑anovulation, with the exclusion of other causes. This definition captures a subset of women with more pronounced endocrine abnormalities. For example, a patient meeting NIH criteria is more likely to exhibit elevated LH, increased fasting insulin, and a higher prevalence of metabolic syndrome compared with those identified solely by Rotterdam criteria.

Androgen Excess Society (AES) criteria align closely with the NIH definition but emphasise biochemical confirmation of hyperandrogenism. The AES guidelines recommend using mass‑spectrometry methods for testosterone measurement whenever possible, to avoid false‑positive results from immunoassays. In clinical practice, adopting AES criteria may improve specificity for androgen excess while still recognising the heterogeneous nature of PCOS.

Metabolic syndrome is a cluster of cardiometabolic risk factors including central obesity, hypertension, dyslipidaemia, and impaired glucose tolerance. Women with PCOS are two‑ to three‑fold more likely to meet metabolic syndrome criteria than age‑matched controls. The presence of metabolic syndrome influences treatment decisions; for instance, a patient with PCOS and hypertension may be preferentially prescribed an oral contraceptive containing drospirenone, which has modest antimineralocorticoid activity, rather than one containing levonorgestrel, which can exacerbate blood pressure.

Insulin sensitiser refers to a class of medications that improve insulin signalling and reduce hyperinsulinaemia. Metformin, a biguanide, is the most commonly used insulin sensitiser in PCOS. Its mechanisms include inhibition of hepatic gluconeogenesis, enhancement of peripheral glucose uptake, and reduction of ovarian androgen production. A practical example: A 28‑year‑old woman with PCOS, BMI = 32 kg/m², and HOMA‑IR = 5.2 Is started on metformin 500 mg twice daily, titrated to 1500 mg three times daily, resulting in a 20 % reduction in serum testosterone after three months.

Thiazolidinediones (TZDs) such as pioglitazone act as peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) agonists, improving insulin sensitivity primarily in adipose tissue. Although effective in reducing insulin resistance, TZDs are less frequently used in PCOS due to concerns about weight gain, fluid retention, and hepatic toxicity. Clinicians may reserve TZDs for patients who cannot tolerate metformin or who have contraindications to its use.

Oral contraceptive pills (OCPs) are first‑line therapy for managing hyperandrogenic symptoms in PCOS. Combination OCPs containing an estrogen component (ethinyl‑estradiol) and a progestin suppress ovarian androgen production by reducing LH pulsatility and increase sex hormone‑binding globulin (SHBG), thereby lowering free testosterone. Progestins differ in androgenic potency; drospirenone and desogestrel have low androgenic activity, while levonorgestrel possesses higher androgenic effects. A case illustration: A patient with severe hirsutism benefits from an OCP containing drospirenone 3 mg/ethinyl‑estradiol 20 µg, resulting in a 30 % increase in SHBG after six weeks.

Anti‑androgen agents such as spironolactone, flutamide, and finasteride block androgen receptors or inhibit 5α‑reductase activity, reducing the conversion of testosterone to dihydrotestosterone (DHT). Spironolactone, at doses of 100‑200 mg daily, is frequently combined with an OCP to enhance hirsutism control. Monitoring for hyperkalaemia is essential, particularly in patients with renal impairment. For example, a woman with PCOS and persistent hirsutism after three months of OCP therapy adds spironolactone 100 mg daily, and her Ferriman‑Gallwey score improves from 12 to 7 after six months.

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that induces ovulation by blocking estrogen feedback at the hypothalamus, thereby increasing GnRH pulse frequency and stimulating LH and FSH release. Clomiphene is typically initiated at 50 mg daily for five days, beginning on cycle day 3–5. Approximately 70‑80 % of women with PCOS will ovulate with clomiphene, though only 30‑40 % achieve pregnancy due to luteal phase defects. An illustrative protocol: A patient who fails to conceive after three clomiphene cycles is switched to letrozole, an aromatase inhibitor, which may improve ovulation rates in PCOS.

Letrozole inhibits aromatase, reducing peripheral conversion of androgens to estrogen and thereby increasing intra‑ovarian androgen levels, which promotes follicular development. Randomised trials have shown higher live‑birth rates with letrozole compared with clomiphene in PCOS‑related infertility. Typical dosing starts at 2.5 Mg daily for five days, with titration up to 7.5 Mg if ovulation does not occur. A practical scenario: A 32‑year‑old woman with PCOS, BMI = 28 kg/m², experiences ovulation after a 5‑mg letrozole regimen, confirmed by a mid‑luteal progesterone of 10 ng/mL.

Gonadotropin therapy involves the administration of exogenous FSH, sometimes combined with LH, to directly stimulate follicular growth in women who are resistant to oral ovulation agents. Recombinant FSH is preferred for its purity and predictable pharmacokinetics. Monitoring includes serial ultrasound assessments of follicular size and serum estradiol levels to avoid ovarian hyperstimulation syndrome (OHSS). For instance, a patient receiving 150 IU of recombinant FSH daily demonstrates a dominant follicle of 18 mm after eight days, prompting hCG trigger for timed intercourse.

In vitro fertilisation (IVF) is considered for PCOS patients who fail to conceive after exhaustive ovulation induction attempts, or for those with severe tubal disease. PCOS patients are at increased risk of OHSS due to heightened ovarian responsiveness. Strategies to mitigate OHSS include using a GnRH antagonist protocol, triggering ovulation with a GnRH agonist instead of hCG, and employing a “freeze‑all” approach. A clinical vignette: A 35‑year‑old woman with PCOS undergoes a GnRH antagonist IVF cycle, receives a GnRH agonist trigger, and all embryos are cryopreserved, resulting in a successful frozen‑embryo transfer without OHSS.

Ovarian drilling is a laparoscopic surgical technique that destroys a portion of the ovarian cortex, reducing theca‑cell mass and consequently androgen production. It is typically reserved for women who are refractory to medical therapy and desire spontaneous ovulation. Success rates for ovulation range from 40‑80 %, but the procedure carries risks of adhesion formation and diminished ovarian reserve. An example: A patient with clomiphene‑resistant PCOS undergoes ovarian drilling, resumes regular menses within three months, and conceives naturally six months post‑procedure.

Weight loss and lifestyle modification are cornerstone interventions for overweight and obese women with PCOS. Even modest weight reductions of 5‑10 % can improve insulin sensitivity, restore ovulatory cycles, and lower androgen levels. Structured programs combining dietary counselling, aerobic exercise, and behavioural therapy yield the most durable outcomes. For example, a 24‑year‑old woman with a BMI of 34 kg/m² follows a 1,200‑kcal low‑glycaemic‑index diet and engages in 150 minutes of moderate‑intensity exercise weekly, achieving a 7 % weight loss and resumption of regular menses after three months.

Glycaemic index (GI) is a measure of carbohydrate quality, reflecting the post‑prandial glucose response. Low‑GI diets attenuate insulin spikes, thereby reducing hyperinsulinaemia and its androgen‑stimulating effects. In practice, substituting high‑GI foods (e.G., White bread) with low‑GI alternatives (e.G., Whole‑grain bread, legumes) can be an effective component of PCOS management. A simple dietary swap: Replacing a breakfast of sugary cereal with oatmeal topped with berries reduces the overall GI load and may improve HOMA‑IR scores over time.

Adipokines are cytokines secreted by adipose tissue, including leptin, adiponectin, and resistin, which influence metabolic and reproductive pathways. In PCOS, leptin levels often correlate with body fat, whereas adiponectin, which enhances insulin sensitivity, is frequently reduced. Understanding adipokine profiles can guide therapeutic decisions; for instance, lifestyle interventions that increase adiponectin may augment insulin‑sensitising drug efficacy.

Leptin signals energy sufficiency to the hypothalamus and modulates GnRH secretion. Hyperleptinaemia in obesity can contribute to hypothalamic resistance, potentially disrupting reproductive hormone balance. In PCOS, leptin may be elevated independently of BMI, suggesting an intrinsic dysregulation. Clinical relevance includes the observation that women with higher leptin levels may experience a blunted response to clomiphene, prompting clinicians to consider alternative ovulation agents.

Adiponectin enhances insulin sensitivity by promoting fatty‑acid oxidation and glucose uptake. Low adiponectin concentrations are associated with increased insulin resistance and hyperandrogenism in PCOS. Interventions that raise adiponectin, such as weight loss, omega‑3 fatty‑acid supplementation, and thiazolidinedione therapy, can improve metabolic parameters. A research example: A pilot study demonstrated a 15 % rise in adiponectin after 12 weeks of aerobic exercise, accompanied by a 10 % reduction in serum testosterone.

Environmental endocrine disruptors are exogenous chemicals that interfere with hormone synthesis, metabolism, or receptor binding. Common agents implicated in PCOS include bisphenol A (BPA) and phthalates, which may alter ovarian steroidogenesis and promote insulin resistance. Epidemiological studies suggest higher urinary BPA concentrations in women with PCOS compared with controls. Practical advice for clinicians includes counselling patients on reducing exposure by avoiding plastic food containers, using glass storage, and limiting consumption of processed foods.

Bisphenol A is a phenolic compound used in the production of polycarbonate plastics and epoxy resins. BPA can bind estrogen receptors and disrupt the hypothalamic‑pituitary‑gonadal axis. In vitro studies show that BPA exposure increases theca‑cell androgen production. While definitive causality remains unproven, clinicians may advise patients to adopt BPA‑avoidance strategies as part of a holistic PCOS management plan.

Phthalates are plasticisers that increase the flexibility of polyvinyl chloride (PVC) products. Like BPA, phthalates exhibit weak estrogenic activity and have been linked to altered menstrual cyclicity and increased androgen levels. Urinary metabolites of di‑2‑ethylhexyl phthalate (DEHP) are often measured in research settings. Patient education can include recommendations to use fragrance‑free personal care products and to avoid microwaving food in plastic containers.

Thyroid function must be assessed in all women with PCOS because thyroid disorders can mimic or exacerbate PCOS features. Hypothyroidism may cause menstrual irregularities, weight gain, and elevated prolactin, while hyperthyroidism can lead to menstrual frequency changes and hirsutism. A standard work‑up includes serum thyroid‑stimulating hormone (TSH) and free thyroxine (fT4). For example, a woman with PCOS and a TSH of 6.5 ΜIU/mL may benefit from levothyroxine replacement, which can normalise menstrual cycles and reduce androgenic symptoms.

Prolactin is a pituitary hormone that, when elevated, can suppress GnRH pulsatility and lead to anovulation. Hyperprolactinaemia must be ruled out before confirming PCOS, especially when menstrual disturbances are prominent. Magnetic resonance imaging (MRI) may be required if prolactin exceeds 100 ng/mL to exclude a prolactinoma. A clinical illustration: A patient with PCOS‑like features and a serum prolactin of 120 ng/mL is diagnosed with a micro‑prolactinoma and started on cabergoline, resulting in restoration of ovulatory cycles.

Autoimmune thyroiditis (Hashimoto’s disease) is the most common cause of hypothyroidism and may coexist with PCOS. The presence of anti‑thyroid peroxidase (anti‑TPO) antibodies can indicate an autoimmune milieu that potentially contributes to insulin resistance. Screening for anti‑TPO antibodies is advisable in PCOS patients with unexplained weight gain or dyslipidaemia.

Cardiovascular risk in PCOS is heightened due to the confluence of metabolic abnormalities, including dyslipidaemia, hypertension, and endothelial dysfunction. Biomarkers such as C‑reactive protein (CRP), homocysteine, and lipoprotein (a) may be elevated. Lifestyle interventions that improve insulin sensitivity also reduce cardiovascular risk. For instance, a 12‑month lifestyle programme incorporating Mediterranean diet principles led to a 12 % reduction in LDL‑cholesterol and a 15 % decrease in systolic blood pressure in a cohort of women with PCOS.

Dyslipidaemia in PCOS typically presents as elevated triglycerides, low high‑density lipoprotein (HDL) cholesterol, and sometimes increased low‑density lipoprotein (LDL) particles. Statin therapy may be indicated for women with persistent lipid abnormalities after lifestyle modification, though teratogenic potential necessitates reliable contraception. A scenario: A 30‑year‑old woman on a high‑dose statin for dyslipidaemia is counselled on the need for effective contraception before conception, and a combined OCP is prescribed concurrently.

Hypertension is more prevalent in PCOS, particularly in women with obesity and insulin resistance. Blood pressure monitoring should be part of routine assessment, and antihypertensive choices must consider reproductive plans. ACE inhibitors and angiotensin‑II receptor blockers are contraindicated in pregnancy, whereas calcium‑channel blockers and beta‑blockers are generally safe. An example: A patient planning pregnancy is switched from losartan to labetalol to achieve better blood pressure control without teratogenic risk.

Psychological impact of PCOS includes increased rates of anxiety, depression, body‑image dissatisfaction, and reduced health‑related quality of life. Screening tools such as the Hospital Anxiety and Depression Scale (HADS) or the Polycystic Ovary Syndrome Health‑Related Quality of Life questionnaire (PCOS‑Q) can identify patients who may benefit from psychological support. A case study: A woman with severe hirsutism and infertility scores 16 on the HADS depression subscale; referral to a cognitive‑behavioural therapist results in improved coping strategies and adherence to treatment.

Patient education is a critical component of PCOS management. Effective education involves explaining the multifactorial nature of the disorder, setting realistic expectations for treatment outcomes, and empowering patients to engage in lifestyle change. Utilising visual aids, such as hormone pathway diagrams, can enhance comprehension. For instance, a clinician uses a simplified diagram highlighting the interplay between insulin, LH, and ovarian androgen production to illustrate why weight loss can diminish hyperandrogenism.

Clinical assessment of PCOS includes a thorough history, physical examination, and targeted investigations. Key historical elements are menstrual pattern, signs of androgen excess, weight trajectory, and family history of metabolic disease. Physical examination should document BMI, waist circumference, skin signs (acne, acanthosis nigricans), and hirsutism using the Ferriman‑Gallwey score. Laboratory evaluation typically includes serum testosterone, SHBG, fasting glucose, insulin, lipid profile, TSH, and prolactin. Imaging, usually trans‑vaginal ultrasound, assesses ovarian morphology. An integrated approach ensures that all diagnostic criteria are considered and that co‑morbidities are identified early.

Biochemical assessment requires an understanding of assay limitations. Testosterone measured by immunoassay may overestimate low concentrations, leading to false‑positive hyperandrogenism diagnoses. LC‑MS/MS is recommended for accuracy, especially when total testosterone is <50 ng/dL. SHBG assays can vary; low SHBG amplifies free androgen levels, so calculating free testosterone using the Vermeulen equation may provide additional insight. A practical tip: When a patient’s total testosterone is borderline, confirmatory testing with LC‑MS/MS can avoid misclassification.

Reference ranges differ between laboratories and are influenced by assay methodology, population demographics, and pre‑analytical variables such as time of day. Clinicians should review the laboratory’s specific reference intervals and consider age‑adjusted cut‑offs when interpreting results. For example, a 22‑year‑old woman’s upper limit for free testosterone may be lower than that for a 35‑year‑old, reflecting physiological changes across the reproductive lifespan.

Assay variability poses a challenge for longitudinal monitoring. Small fluctuations in testosterone or insulin levels may reflect laboratory noise rather than true clinical change. When tracking treatment response, it is advisable to use the same laboratory and assay technique throughout the course of therapy. A clinician can document assay details in the patient’s chart to ensure consistency.

Mass spectrometry techniques, such as LC‑MS/MS, have become the gold standard for steroid hormone measurement due to superior specificity and sensitivity. Although more costly and requiring specialised equipment, these methods reduce cross‑reactivity and improve diagnostic confidence. For research settings, mass spectrometry enables the detection of subtle hormonal shifts that may be missed by conventional immunoassays.

Immunoassay remains widely used because of its accessibility and rapid turnaround. However, clinicians must be aware of its limitations, particularly for low‑concentration steroids. When interpreting immunoassay results, consider potential interferences such as heterophilic antibodies or binding protein abnormalities. An example: A patient with high SHBG may have an artificially low free testosterone when calculated from total testosterone measured by immunoassay.

Standardisation initiatives aim to harmonise hormone assays across laboratories, facilitating comparability of results. Organizations such as the International Federation of Clinical Chemistry (IFCC) provide reference measurement procedures. Adoption of standardised protocols improves the reliability of PCOS diagnostic criteria across different clinical settings.

Cost‑effectiveness analyses compare the economic impact of various PCOS interventions. For instance, lifestyle programmes that achieve modest weight loss may be more cost‑effective than pharmacological therapy alone, given the long‑term reduction in diabetes and cardiovascular disease risk. Decision‑analytic models can guide policymakers in allocating resources for PCOS services.

Research gaps persist in the endocrine domain of PCOS. Areas requiring further investigation include the precise genetic determinants of insulin resistance, the long‑term cardiovascular outcomes of early‑life interventions, and the impact of emerging endocrine disruptors on ovarian function. Encouraging multidisciplinary collaboration and incorporating novel biomarkers may advance the field.

Future directions encompass personalised medicine approaches that integrate genetic profiling, metabolomics, and patient‑reported outcomes. Tailoring treatment based on an individual’s insulin sensitivity, androgen levels, and reproductive goals holds promise for improving efficacy while minimising adverse effects. For example, pharmacogenomic testing could identify women who are likely to respond to clomiphene versus letrozole, streamlining fertility treatment pathways.

Gonadotropin‑releasing hormone agonists (GnRH‑a) are used in controlled ovarian hyperstimulation protocols and in the management of severe hyperandrogenism. By initially stimulating, then down‑regulating pituitary GnRH receptors, GnRH‑a can suppress LH and androgen production. In PCOS, long‑acting GnRH‑a may be employed pre‑operatively to reduce ovarian size and vascularity before ovarian drilling, thereby decreasing intra‑operative bleeding risk.

GnRH antagonists provide a rapid, reversible suppression of GnRH receptors without the initial flare effect of agonists. In IVF cycles for PCOS patients, GnRH antagonists are preferred because they reduce the incidence of OHSS. A typical protocol involves starting the antagonist on stimulation day 5 and continuing until the day of hCG trigger. This strategy allows flexible scheduling and mitigates the risk of excessive ovarian response.

Luteal phase support after ovulation induction is crucial for maintaining the endometrium and improving implantation rates. Progesterone supplementation, either vaginally or intramuscularly, is standard practice. In PCOS, luteal phase defects are common, and inadequate progesterone may contribute to early pregnancy loss. An example: A patient receiving clomiphene and hCG trigger is prescribed vaginal micronised progesterone 400 mg nightly, resulting in a luteal progesterone of 12 ng/mL on day 7 post‑ovulation.

Metabolic monitoring is a lifelong responsibility for women with PCOS. Annual assessments should include fasting glucose, HbA1c, lipid profile, blood pressure, and BMI. Early detection of pre‑diabetes allows timely initiation of preventive strategies. A practical schedule: A 26‑year‑old woman with PCOS is screened every 12 months; after two years, her HbA1c rises from 5.4 % To 5.8 %, Prompting intensification of lifestyle counselling and a low‑dose metformin regimen.

Nutrition counselling should be tailored to the individual’s cultural preferences, metabolic profile, and weight goals. Emphasising whole‑grain carbohydrates, lean protein, and unsaturated fats can improve insulin sensitivity. The DASH (Dietary Approaches to Stop Hypertension) diet, rich in fruits, vegetables, and low‑fat dairy, has been shown to reduce blood pressure and improve lipid parameters in PCOS. A dietitian may create a meal plan with a daily caloric target of 1,600 kcal, incorporating a 30 % reduction in refined sugars, leading to measurable improvements in HOMA‑IR after 16 weeks.

Physical activity recommendations for PCOS include at least 150 minutes of moderate‑intensity aerobic exercise per week, combined with resistance training twice weekly. Exercise improves insulin sensitivity independent of weight loss. For example, a patient who adds three 45‑minute brisk‑walking sessions per week experiences a 10 % reduction in fasting insulin after six weeks, despite no change in body weight.

Behavioural therapy addresses the psychological barriers to sustained lifestyle change. Motivational interviewing techniques can enhance adherence to diet and exercise regimes. A case: A woman with PCOS and recurrent weight‑gain cycles engages in weekly behavioural sessions, resulting in a sustained 5 % weight loss and regularisation of menstrual cycles over a 12‑month period.

Pharmacologic hierarchy for ovulation induction in PCOS generally follows a stepwise approach: First‑line oral agents (clomiphene or letrozole), followed by metformin when insulin resistance is present, then gonadotropins for clomiphene‑resistant cases, and finally assisted reproductive technologies if ovulation induction fails. Understanding the endocrine rationale for each step enables clinicians to personalise therapy. For instance, a patient with high BMI and IR may benefit from combined letrozole‑metformin therapy, exploiting synergistic mechanisms to improve ovulation rates.

Oral contraceptive selection must consider individual risk factors. Women with a history of venous thromboembolism should avoid estrogen‑containing OCPs and may require a progestin‑only method. In contrast, a patient with acne may benefit from an OCP containing drospirenone, which has anti‑androgenic properties. An algorithmic approach assists in matching OCP composition to clinical presentation.

Progestin choice influences metabolic outcomes. Progestins with higher androgenic activity (e.G., Levonorgestrel) may exacerbate insulin resistance, whereas those with anti‑androgenic properties (e.G., Desogestrel) are more favourable for metabolic health. Selecting a low‑androgenic progestin can mitigate the risk of worsening dyslipidaemia in overweight patients.

Selective estrogen receptor modulators (SERMs) other than clomiphene, such as tamoxifen and raloxifene, have been investigated for ovulation induction but are not routinely recommended due to limited efficacy and safety data. Their primary role remains in oncology and osteoporosis management.

Anti‑Müllerian hormone measurement can guide fertility counselling. Women with very high AMH (>10 ng/mL) may experience a “hyper‑responsive” ovary, increasing the risk of OHSS during stimulation. In such cases, a “low‑dose” gonadotropin protocol or a “freeze‑all” strategy is advisable. Conversely, low AMH may indicate diminished ovarian reserve, prompting earlier consideration of IVF.

Adrenal androgen assessment distinguishes ovarian from adrenal sources of excess androgens. Elevated DHEA‑S suggests adrenal contribution, which may be seen in congenital adrenal hyperplasia (CAH) or adrenal tumors. A dexamethasone suppression test can differentiate CAH (lack of suppression) from PCOS (suppressed). For example, a patient with DHEA‑S of 450 µg/dL and inadequate suppression after dexamethasone is evaluated for non‑classic CAH.

Congenital adrenal hyperplasia (non‑classic) is a differential diagnosis for hyperandrogenism. The 21‑hydroxylase deficiency variant presents with mild cortisol insufficiency and excess androgen production. Genetic testing for CYP21A2 mutations confirms the diagnosis. Treatment with low‑dose glucocorticoids (e.G., Hydrocortisone) can reduce adrenal androgen output, improving hirsutism and menstrual regularity.

Glucose tolerance testing remains the gold standard for detecting impaired glucose metabolism in PCOS. The 75‑g OGTT measures plasma glucose at baseline, 30, 60, 90, and 120 minutes. A 2‑hour glucose level of 140‑199 mg/dL indicates impaired glucose tolerance, while ≥200 mg/dL defines diabetes. Early identification enables timely initiation of lifestyle or pharmacologic interventions to prevent progression.

HbA1c provides a convenient measure of average glycaemia over three months. Although less sensitive to post‑prandial spikes than OGTT, HbA1c is useful for routine monitoring. In PCOS, an HbA1c ≥5.7 % Signals pre‑diabetes, prompting intensified metabolic management. A patient with an HbA1c of 5.8 % May be counseled on dietary carbohydrate reduction and started on metformin, even in the absence of overt hyperglycaemia.

Cardiovascular imaging such as carotid intima‑media thickness (CIMT) can detect early atherosclerotic changes in PCOS. Studies show increased CIMT in women with PCOS independent of traditional risk factors, suggesting an intrinsic vascular risk. While not routinely recommended, CIMT may be considered in high‑risk individuals for early intervention.

Inflammatory markers like high‑sensitivity CRP (hs‑CRP) are often elevated in PCOS, reflecting low‑grade inflammation. Elevated hs‑CRP correlates with insulin resistance and may predict cardiovascular events. Lifestyle modification, weight loss, and statin therapy can reduce hs‑CRP levels. A patient with hs‑CRP of 3.5 Mg/L experiences a reduction to 2.0 Mg/L after a 12‑week exercise programme.

Genetic predisposition in PCOS involves multiple loci identified through genome‑wide association studies (GWAS). Genes related to insulin signalling (e.G., INSR), steroidogenesis (e.G., CYP11A1), and gonadotropin regulation (e.G., LHCGR) have been implicated.